Cyclosporine

Cyclosporine

SCHEMBL22123717

C/C=C/CC(C)C(O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPIA

The experimentally established mechanism targets of Cyclosporine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPIA known ✓ P62937 5/20 1.00
ABCB1 P08183 13/20 1.00
PPP3CA Q08209 3/20 1.00
FKBP1B P68106 2/20 1.00
MEN1 O00255 1/20 1.00
NPC1 O15118 1/20 1.00
ABCC3 O15438 1/20 1.00
GMNN O75496 1/20 1.00
USP2 O75604 1/20 1.00
SLCO2B1 O94956 1/20 1.00
ABCB11 O95342 1/20 1.00
LMNA P02545 1/20 1.00
POLB P06746 1/20 1.00
CYP3A4 P08684 1/20 1.00
MAPT P10636 1/20 1.00
RARB P10826 1/20 1.00
CYP2C9 P11712 1/20 1.00
CYP3A5 P20815 1/20 1.00
TACR2 P21452 1/20 1.00
PPIB P23284 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclosporine SCHEMBL21170318 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
SCHEMBL23382247 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
Cyclosporine SCHEMBL24239446 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
Cyclosporine SCHEMBL24224445 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
Cyclosporine SCHEMBL25083206 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
Cyclosporine SCHEMBL24239035 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
Cyclosporine SCHEMBL23192320 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
SCHEMBL23110210 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
Cyclosporine SCHEMBL24239036 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1
Cyclosporine SCHEMBL23192319 1.00 ABCB1 (1.00) ABCB1PPIAPPP3CAFKBP1BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104958754-A Cyclosporine cream for treating lupus erythematosus or psoriasis, method for manufacturing cyclosporine cream and application thereof JIUHUI PHARMACEUTICAL CO LTD 2015-10-07 CN claimed
US-12458704-B2 Multimeric elastin-like polypeptides UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2025-11-04 US disclosed
US-12070442-B2 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease SURFACE OPHTHALMICS, INC. (US) 2024-08-27 US disclosed
US-20230277557-A1 PHARMACEUTICAL KITS AND THEIR USE FOR TREATING DRY EYE DISEASE SURFACE OPHTHALMICS INC (US) 2023-09-07 US disclosed
US-20230181752-A1 MULTIMERIC ELASTIN-LIKE POLYPEPTIDES UNIVERSITY OF SOUTHERN CALIFORNIA 2023-06-15 US disclosed
EP-3899048-A1 PYRROLOBENZODIAZEPINE RESISTANCE ADC Therapeutics SA (CH) 2021-10-27 EP disclosed
CN-108697644-B Method for producing particles 株式会社理光 2021-10-22 CN disclosed
CN-108675935-B Preparation method of 1, 1-diaryl alkane compound 南昌航空大学 2020-08-28 CN disclosed
WO-2020127573-A1 PYRROLOBENZODIAZEPINE RESISTANCE ADC THERAPEUTICS SA (CH) 2020-06-25 WO disclosed
CN-104958754-B A kind of cyclosporin emulsifiable paste and its preparation method and application for treating lupus erythematosus or psoriasis 惠州市九惠制药股份有限公司 2019-04-23 CN disclosed
CN-104958754-A Cyclosporine cream for treating lupus erythematosus or psoriasis, method for manufacturing cyclosporine cream and application thereof JIUHUI PHARMACEUTICAL CO LTD 2015-10-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458704-B2 Multimeric elastin-like polypeptides MICA, SERPINA2, DNASE1L3 PPIA 443/4885ABCB1 281/4885PPP3CA 333/4885
US-12070442-B2 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease EYA3, HSD3B1, HMGCR PPIA 940/4885ABCB1 1144/4885PPP3CA 12/4885
US-20230181752-A1 MULTIMERIC ELASTIN-LIKE POLYPEPTIDES MICA, SERPINA2, DNASE1L3 PPIA 443/4885ABCB1 281/4885PPP3CA 333/4885
US-20230277557-A1 PHARMACEUTICAL KITS AND THEIR USE FOR TREATING DRY EYE DISEASE TSLP, SERPINA6, IL5 PPIA 2130/4885ABCB1 1265/4885PPP3CA 1102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.